Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
48.77 USD   +1.10%
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 11:15 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

11/03/2022 | 06:47am EST

Intra-Cellular Therapies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 71.87 million compared to USD 22.21 million a year ago. Net loss was USD 53.51 million compared to USD 76.91 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.95 a year ago.
For the nine months, revenue was USD 162.45 million compared to USD 58.13 million a year ago. Net loss was USD 212.23 million compared to USD 198.39 million a year ago. Basic loss per share from continuing operations was USD 2.26 compared to USD 2.44 a year ago.


ę S&P Capital IQ 2022
All news about INTRA-CELLULAR THERAPIES, INC.
01/13RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform..
MT
01/09Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
01/09Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morg..
CI
01/03Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
AQ
2022Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations a..
AQ
2022Insider Sell: Intra-Cellular Therapies
MT
2022Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
More news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
More recommendations
Financials (USD)
Sales 2022 249 M - -
Net income 2022 -271 M - -
Net cash 2022 272 M - -
P/E ratio 2022 -17,0x
Yield 2022 -
Capitalization 4 619 M 4 619 M -
EV / Sales 2022 17,5x
EV / Sales 2023 9,93x
Nbr of Employees 512
Free-Float 97,4%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 48,77 $
Average target price 69,62 $
Spread / Average Target 42,7%
EPS Revisions
Managers and Directors
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
INTRA-CELLULAR THERAPIES, INC.-8.84%4 569
VERTEX PHARMACEUTICALS9.18%80 930
REGENERON PHARMACEUTICALS, INC.2.73%79 159
WUXI APPTEC CO., LTD.20.37%42 279
BIONTECH SE-4.99%34 686
BEIGENE, LTD.18.96%27 392